An Indian startup ecosystem of the youth, for the youth, by the youth
At the Prarambh: Startup India International Summit, Prime Minister Narendra Modi announced the launch of Rs 1,000-crore Startup India Seed Fund to support startups and help budding entrepreneurs pursue innovative ideas.
0 claps
Good morning!
If you re a young startup (and a very early stage one at that), you have good reason to cheer!
“We are trying to create a startup ecosystem that is based on the principle ‘of the youth, by the youth, for the youth,” emphasised PM Modi.
Prime Minister Narendra Modi
He lauded startups for powering India’s drive to be self-reliant amidst the COVID-19 pandemic. Startups, Modi said, are changing the very “demographic character of business.”
Earlier, the independent Data and Safety Monitoring Board (DSMB) had reviewed the safety data from the Phase 2 clinical trial of the vaccine and recommended it for Phase 3 clinical trial.
Dr Reddy s Sputnik Vaccine Gears Up for Phase 3 Clinical Trial, Gets DCGI Nod
The phase 3 study of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study
| 16 Jan 2021 7:20 AM GMT
NEW DELHI: Hyderabad based, Dr Reddy s Laboratories announced that the Drugs Control General of India (DCGI) has given them the nod to conduct phase 3 clinical trial for the Sputnik V vaccine.
Earlier, GV Prasad, Co-chairman & MD of Dr Reddy s Laboratories said, The phase 2 study in India conducted by Dr Reddy s & RDIF showed a very good safety profile. The further reinforces our confidence in the safety of Sputnik V, which has now been administered to more than 1 million people in Russia & 3000,000 people in Argentina. We are working towards fast-tracking the launch of the Sputnik V vaccine in India.
Dr Reddy s Gets Indian Drug Regulator s Nod For Phase-3 Trials Of Russian Sputnik V Covid-19 Vaccine In India
Russian Sputnik V Covid-19 vaccine (Pic Via Sputnik V website)
Pharma major Dr Reddy s Laboratories Ltd on Friday announced that it has received approval from the Drugs Control General of India (DCGI) to conduct Phase 3 clinical trial for the Sputnik V vaccine in India.
The Phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomised, double-blind, parallel-group, placebo-controlled study in India, the Hyderabad-based company said in a statement.
The company said that the independent Data and Safety Monitoring Board (DSMB) reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.
Read more about Dr. Reddys receives DCGI approval to conduct Phase 3 clinical trial for Sputnik V vaccine in India on Business Standard. The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.